MedPath

Oscotec Inc.

Oscotec Inc. logo
🇰🇷South Korea
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

11

Active:5
Completed:6

Trial Phases

3 Phases

Early Phase 1:1
Phase 1:8
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 1
8 (72.7%)
Phase 2
2 (18.2%)
Early Phase 1
1 (9.1%)

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors

Phase 1
Active, not recruiting
Conditions
Advanced Solid Tumor
Interventions
First Posted Date
2023-08-02
Last Posted Date
2024-02-21
Lead Sponsor
Oscotec Inc.
Target Recruit Count
36
Registration Number
NCT05971862
Locations
🇰🇷

Yonsei University College of Medicine Severance Hospital, Seoul, Korea, Republic of

🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

A Study of the Absorption, Metabolism, and Excretion of [14C]-SKI-O-703 Following a Single Oral Dose in Healthy Male Subjects

Early Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: .[14C]-SKI-O-703
First Posted Date
2021-09-13
Last Posted Date
2022-04-20
Lead Sponsor
Oscotec Inc.
Target Recruit Count
8
Registration Number
NCT05042986
Locations
🇺🇸

Labcorp Clinical Research Unit Inc., Madison, Wisconsin, United States

A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.

Phase 2
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: Placebo
First Posted Date
2019-08-15
Last Posted Date
2024-07-31
Lead Sponsor
Oscotec Inc.
Target Recruit Count
163
Registration Number
NCT04057118
Locations
🇺🇸

Oscotec Investigational Site (Site 3110), Beverly Hills, California, United States

🇺🇸

Oscotec Investigational Site (Site 3105), Upland, California, United States

🇺🇸

Oscotec Investigational (Site 3104), Miami Lakes, Florida, United States

and more 37 locations

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

Phase 2
Completed
Conditions
Immune Thrombocytopenia
Interventions
Drug: Placebo oral tablet
First Posted Date
2019-08-14
Last Posted Date
2024-07-10
Lead Sponsor
Oscotec Inc.
Target Recruit Count
61
Registration Number
NCT04056195
Locations
🇺🇸

University of Southern California, 1441 Eastlake Ave., Los Angeles, California, United States

🇺🇸

Duke University Medical Center, 2301 Erwin Road, Durham, North Carolina, United States

🇺🇸

East Carolina University, 600 Moye Boulevard, Greenville, North Carolina, United States

and more 24 locations

Study to Find a Safe and Effective Dose of SKI-G-801 in the Treatment of Patients With Acute Myeloid Leukemia (AML)

Phase 1
Completed
Conditions
Acute Myeloid Leukemia
Interventions
First Posted Date
2018-06-20
Last Posted Date
2024-02-21
Lead Sponsor
Oscotec Inc.
Target Recruit Count
14
Registration Number
NCT03564288
Locations
🇺🇸

USC Norris Comprehensive Cancer Center, Clinical Investigations Support Office (CISO), 1441 Eastlake Ave., Rm. 7327, Los Angeles, California, United States

🇺🇸

Innovative Clinical Research Institute, Whittier, California, United States

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.